Use of a parathyroid hormone peptide (PTH(1-34))-enriched fibrin hydrogel for the treatment of a subchondral cystic lesion in the proximal interphalangeal joint of a warmblood filly.

This research describes the successful use of a parathyroid hormone peptide-enriched fibrin hydrogel in treating a bone cyst in a horse’s joint. The researchers provide evidence that this treatment option can help improve the postoperative prognosis for horses, which otherwise face a poor outlook.

Background

• The study focuses on the treatment of subchondral bone cysts in horses, specifically a warmblood filly (a young female horse).
• Subchondral bone cysts are fairly common in horses, and the prognosis after surgery is often poor, particularly in older horses.
• There has been active research into particularly effective treatment methods to enhance the prognosis post-surgery.

Use of Parathyroid Hormone Peptide (PTH(1-34))-Enriched Fibrin Hydrogel

• PTH(1-34) is a fragment of parathyroid hormone. It was covalently attached to a fibrin hydrogel and used to treat the bone cyst.
• The cyst was localized using computer-assisted orthopaedic surgery, followed by a procedure called curettage to remove the diseased tissue.
• The space created by the curettage was then filled with the PTH(1-34)-enriched fibrin hydrogel.

Results and Implications

• The treatment resulted in quick healing of the cyst without any complications.
• This outcome is significant as it indicates that the local application of PTH(1-34) in a fibrin hydrogel could improve the prognosis after surgical management of subchondral bone cysts.
• As such, this offers a new method in the treatment of these common bone cysts in horses, with potential benefits for veterinary practice and horse health.